Outpace Bio
Outpace Bio is a biotechnology company using AI-powered protein design to create programmable cell therapies for treating solid tumors.
Secondary Market Price
How Outpace Bio Measures Up
To help you manage your Outpace Bio equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Outpace Bio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Outpace Bio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Outpace Bio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Outpace Bio is a biotechnology research company founded in 2020 that develops cell therapies using protein design and cellular engineering. The company, based in Seattle, Washington, focuses on programming cells to overcome efficacy and safety barriers in treatments, particularly for solid tumors. It utilizes a suite of proprietary technologies, including OutLast™ to drive persistent cell therapy activity, Co-LOCKR™ to achieve specificity, and the OUTDRIVE™ platform for in vivo CAR-T cell therapy. Since its founding, the company has grown to employ between 51 and 200 people and was recognized as the highest-ranked biotech company on the GeekWire 200 list of top startups in the Seattle area.
The company is working toward multiple platform and program milestones set for 2026, with a focus on its in vivo CAR-T platform and the clinical validation of its AI-designed protein technology. Outpace Bio has recently presented updates on its pipeline and platforms at industry events, including ARM’s Meeting on the Mesa and the JPMorgan Healthcare Conference. In September 2024, the company announced it had raised $144 million in a Series B funding round led by RA Capital Management.
- RA Capital Management
- Qatar Investment Authority
- Surveyor Capital
- Sheatree Capital
- Black Opal Ventures
- Alexandria Venture Investments
- ARTIS Ventures
- Playground Global
- Bristol Myers Squibb
- Abstract Ventures
- Civilization Ventures
- Mubadala Capital
- Breton Capital Ventures
- WRF Capital
- Sahsen Ventures
- Co-Founder, Marc Lajoie
- Co-Founder, Scott Boyken
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Outpace Bio worth joining?
Deciding whether to join a startup involves carefully weighing the total compensation package, including the potential value of your equity grant. Platforms like Prospect can help you analyze the company and compare your equity offer against the market to make an informed decision.
What should I do with my Outpace Bio stock?
The right strategy for your stock depends on your personal financial situation, risk tolerance, and the company's projected growth. Using a tool like Prospect can help you develop a custom plan for exercising options and managing your equity to align with your goals.
Can you sell Outpace Bio stock?
As a private company, you can typically sell shares only during specific liquidity events, such as a tender offer or on a secondary market. Prospect offers Tender Offer Tools to help you decide how much to sell and which shares are most tax-optimal.
How can I find the value of my Outpace Bio stock?
The value of private stock is typically based on the company's most recent 409A valuation, but this doesn't reflect its future potential. To get a better forecast, Prospect uses proprietary predictive models that analyze various data points to project the future value of your shares.
What is Outpace Bio's equity worth?
The true worth of private company equity remains uncertain until a liquidity event like an IPO, but you can estimate its potential value. Financial modeling platforms like Prospect can project a range of likely outcomes for your equity based on market data and company performance metrics.
What is Outpace Bio's stock ticker symbol?
Outpace Bio is a private company and does not have a stock ticker symbol, as these are reserved for companies that trade on public stock exchanges. You will not find it listed on exchanges like the NYSE or NASDAQ until after a potential initial public offering (IPO).
Can I buy or sell Outpace Bio stock?
Selling private stock is sometimes possible through secondary markets, while buying is generally limited to exercising your employee stock options. Platforms such as Prospect provide tools and strategies for both exercising options and navigating opportunities to sell shares.
What is the criteria to buy or invest in Outpace Bio stock?
Investing in a private company like Outpace Bio is typically restricted to employees receiving equity compensation or accredited investors and venture capital firms. The general public cannot purchase shares until the company goes public through an IPO.
